193 related articles for article (PubMed ID: 6953278)
1. Further studies on the relationship between allotransplantability and the presence of the cell surface glycoprotein epiglycanin in the TA3-MM mouse mammary carcinoma ascites cell.
Miller SC; Codington JF; Klein G
J Natl Cancer Inst; 1982 Jun; 68(6):981-8. PubMed ID: 6953278
[TBL] [Abstract][Full Text] [Related]
2. Isolation and partial characterization of an epiglycanin-like glycoprotein from a new non-strain-specific subline of TA3 murine mammary adenocarcinoma.
Codington JF; Cooper AG; Miller DK; Slayter HS; Brown MC; Silber C; Jeanloz RW
J Natl Cancer Inst; 1979 Jul; 63(1):153-61. PubMed ID: 286825
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical and morphological characterization of a new allotransplantable mammary carcinoma ascites subline, TA3-St/ticol/-A.
Codington JF; Dalianis T; Miller SC; Das HR; Klein G; Lampert LA; Silber C; Darby DM; Jeanloz RW
Cancer Res; 1983 Sep; 43(9):4364-72. PubMed ID: 6871869
[TBL] [Abstract][Full Text] [Related]
4. Loss of strain specificity of the TA3-St subline: evidence for the role of epiglycanin in mouse allogeneic tumor growth.
Cooper AG; Codington JF; Miller DK; Brown MC
J Natl Cancer Inst; 1979 Jul; 63(1):163-9. PubMed ID: 221714
[TBL] [Abstract][Full Text] [Related]
5. Cell surface characteristics of an allotransplantable TA3 ascites subline resulting from a process of immunoselection.
Codington JF; Das HR; Dalianis T; Klein G; Miller SC; Silber C; Lampert LA; Darby DM; Jeanloz RW
Cancer Res; 1983 Sep; 43(9):4373-81. PubMed ID: 6871870
[TBL] [Abstract][Full Text] [Related]
6. Further studies on the relationship between large glycoprotein molecules and allotransplantability in the TA3 tumor of the mouse: studies on segregating TA3-HA hybrids.
Codington JF; Klein G; Cooper AG; Lee N; Brown MC; Jeanloz RW
J Natl Cancer Inst; 1978 Apr; 60(4):811-8. PubMed ID: 633390
[TBL] [Abstract][Full Text] [Related]
7. Comparative lectin-binding and agglutination properties of the strain-specific, TA-3-St, and the non-strain-specific, TA3-Ha, murine mammary carcinoma ascites sublines. Further studies of receptors in epiglycanin.
Matsumoto I; Codington JF; Jahnke MR; Jeanloz RW; Osawa T
Carbohydr Res; 1980 Apr; 80(1):179-89. PubMed ID: 7363275
[TBL] [Abstract][Full Text] [Related]
8. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA).
Fung PY; Longenecker BM
Cancer Res; 1991 Feb; 51(4):1170-6. PubMed ID: 1825477
[TBL] [Abstract][Full Text] [Related]
9. Epiglycanin as a membrane glycoprotein. Isolation of plasma membrane from the TA3-Ha tumor cell.
Schmit A; Condington JF; Slayter HS
Carbohydr Res; 1986 Aug; 151():173-84. PubMed ID: 3768886
[TBL] [Abstract][Full Text] [Related]
10. Different progression of tumor xenografts between mucin-producing and mucin-non-producing mammary adenocarcinoma-bearing mice.
Sugihara I; Yoshida M; Shigenobu T; Takagi H; Maruyama K; Takeuchi N; Toda M; Inoue M; Nakada H
Cancer Res; 2006 Jun; 66(12):6175-82. PubMed ID: 16778191
[TBL] [Abstract][Full Text] [Related]
11. Antibody to epiglycanin and radioimmunoassay to detect epiglycanin-related glycoproteins in body fluids of cancer patients.
Codington JF; Bhavanandan VP; Bloch KJ; Nikrui N; Ellard JV; Wang PS; Jeanloz RW
J Natl Cancer Inst; 1984 Nov; 73(5):1029-38. PubMed ID: 6208403
[TBL] [Abstract][Full Text] [Related]
12. Relation of human blood-groups MN to cancer cell surface antigens and to receptors for oncogenic viruses.
Springer GF; Desai PR
Ann Clin Lab Sci; 1974; 4(4):294-8. PubMed ID: 4142544
[TBL] [Abstract][Full Text] [Related]
13. Ultrastructural and histochemical differences in cell surface properties of strain-specific and nonstrain-specific TA3 adenocarcinoma cells.
Miller SC; Hay ED; Codington JF
J Cell Biol; 1977 Mar; 72(3):511-29. PubMed ID: 838766
[TBL] [Abstract][Full Text] [Related]
14. The mucin epiglycanin on TA3/Ha carcinoma cells prevents alpha 6 beta 4-mediated adhesion to laminin and kalinin and E-cadherin-mediated cell-cell interaction.
Kemperman H; Wijnands Y; Wesseling J; Niessen CM; Sonnenberg A; Roos E
J Cell Biol; 1994 Dec; 127(6 Pt 2):2071-80. PubMed ID: 7528749
[TBL] [Abstract][Full Text] [Related]
15. Intracellular pathway of a mucin-type membrane glycoprotein in mouse mammary tumor cells.
Watkins SC; Slayter HS; Codington JF
Carbohydr Res; 1991 Jun; 213():185-200. PubMed ID: 1933937
[TBL] [Abstract][Full Text] [Related]
16. Site dependency of TA3 Ha allotransplantability.
Hagmar B; Ryd W
Transplantation; 1977 Jan; 23(1):93-7. PubMed ID: 835167
[TBL] [Abstract][Full Text] [Related]
17. Two kinds of antigen suppression in tumor cells revealed by cell fusion.
Klein G; Friberg S; Harris H
J Exp Med; 1972 Apr; 135(4):839-49. PubMed ID: 5018053
[TBL] [Abstract][Full Text] [Related]
18. Immunity to a TA3 tumor subline that grows in allogeneic hosts elicited by strain-specific TA3 tumor cells.
Lippman MM; Venditti JM; Kline I; Elam DL
Cancer Res; 1973 Apr; 33(4):679-84. PubMed ID: 4696468
[No Abstract] [Full Text] [Related]
19. In vivo release of glycoprotein I from the Ha subline of TA3 murine tumor into ascites fluid and serum.
Cooper AG; Codington JF; Brown MC
Proc Natl Acad Sci U S A; 1974 Apr; 71(4):1224-8. PubMed ID: 4524634
[TBL] [Abstract][Full Text] [Related]
20. Cell-surface macromolecular and morphological changes related to allotransplantability in the TA3 tumor.
Codington JF; Frim DM
Biomembranes; 1983; 11():207-58. PubMed ID: 6338947
[No Abstract] [Full Text] [Related]
[Next] [New Search]
